1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is the most common form of dementia in the elderly. It is a progressive neurodegenerative disorder characterised by a decline in cognitive function and also profound alterations in mood and behaviour \[[@B1]\]. The pathology of the disease is characterised by the presence of extracellular amyloid peptide deposits, soluble amyloid *β*-protein and hyperphosphorylated tau protein leading to the formation of intracellular neurofibrillary tangles in the brain. The aetiology and pathogenesis of the disease are currently poorly understood, and the present management is to a large extent symptomatic and focused on ameliorating the cognitive deficits \[[@B2]\]. However, although many hypotheses have been put forward for the aetiology of the disease, increased inflammation \[[@B3]\] and oxidative stress \[[@B4]\] appear to be key features contributing to the pathology of the disease.

The omega-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) have well-characterised effects on inflammation \[[@B5]\] and may have neuroprotective effects in a number of neurodegenerative conditions including AD \[[@B6]\]. The purpose of this paper is to review the neuroprotective effects of EPA and DHA in AD with emphasis on their potential for modulating amyloidosis and the increased oxidative stress and inflammation seen with AD and explore their potential application as therapeutic agents.

2. Amyloid *β*-Peptide {#sec2}
======================

A major hallmark of AD is the overproduction of amyloid *β*-peptide (A*β*), which results in the formation of plaques. A*β* peptides are produced by successive proteolysis of amyloid precursor protein (APP) by *β*-site APP-cleaving enzyme-1 (BACE1) followed by *γ*-secretase \[[@B7]--[@B9]\]. This cleavage is imprecise and produces A*β* variants, which include those ending at residues 40 (A*β* ~40~) and 42 (A*β* ~42~) \[[@B10]\]. The A*β* ~42~ is deposited earliest and most abundantly in plaques \[[@B11]\]. A*β* has been shown to induce lipid peroxidation in brain cell membranes and increase production of the lipid peroxidation products 4-hydroxynonenal and acrolein, and this may in part account for neurodegeneration in AD brain \[[@B12]\].

Several groups have investigated the role of DHA-enriched diets in animal models of AD and amyloidosis. In a series of studies Hashimoto and colleagues pretreated rats with DHA (300 mg/kg per day for 12 weeks) before an infusion of A*β* ~1-40~ \[[@B13]--[@B15]\]. DHA had a significantly protective effect against the decrease in learning ability and reduced the oxidative stress induced by the A*β* infusion in the cerebral cortex and hippocampus. Pretreatment with DHA also prevented A*β*-induced impairment of an avoidance ability-related memory function. This group also investigated the protective effects of the DHA pretreatment before A*β* infusion on synaptosomal membranes properties. DHA content significantly increased along with both lateral and rotational membrane fluidity, whereas the cholesterol to phospholipid molar ratio and lipid peroxidation decreased.

Elevated cholesterol increases A*β* levels in both *in vitro* and *in vivo*models of AD, and the generation, accumulation, and clearance of A*β* are regulated by cholesterol \[[@B16]--[@B18]\], suggesting an important role for cholesterol in the pathogenesis of AD. Indeed, cholesterol is now a recognized risk factor in the pathogenesis of AD \[[@B18]\]. Furthermore, A*β* generation may be determined by dynamic interactions of APP with lipid rafts, since APP inside rafts undergoes cleavage by *β*-secretase, whereas APP outside rafts undergoes cleavage by *α*-secretase \[[@B19]\]. Lipid rafts are lateral assemblies of sphingolipids and cholesterol within the membrane \[[@B20]\], and it has been suggested that age-related increases in cholesterol in lipid rafts provides a cooperative environment for accumulation of A*β* in plasma membranes \[[@B21]\]. It is therefore of interest to note that omega-3 PUFAs reduce the level of cholesterol in neuronal membranes \[[@B22]\], moreover cholesterol has a low affinity for DHA-containing phospholipids and therefore alterations in the level of membrane DHA will affect the formation of lipid rafts \[[@B23], [@B24]\]. It may be that the effects of DHA on cholesterol levels and lipid raft formation represent an important, but as-yet relatively unexplored, neuroprotective mechanism.

Recent work by Green and coworkers has shown that DHA reduces the levels of soluble and intraneuronal A*β* and somatodendritic tau protein in the 3xTg AD mouse model \[[@B25]\]. The reduction was attributed to a decrease in the steady-state levels of presenilin 1. Importantly, when DHA was combined with either arachidonic or docosapentaenoic acids (both omega-6 PUFAs) the efficacy of DHA diminished over time, with the effects lost by 9 months. However, the additional presence of docosapentaenoic acid in the diet reduced levels of early-stage phospho-tau epitopes, which correlated with the positive outcome of a reduction in phosphorylated (activated) c-Jun N-terminal kinase, a putative tau kinase. It may be that the interrelationship between omega-6 and omega-3 PUFAs is a further important but neglected area of research. DHA has also been shown to significantly increase levels of the sorting protein LR11/SorLA in primary rat neurons, aged nontransgenic mice, and aged DHA-depleted APPsw AD mice \[[@B26]\]. This increase reduces the trafficking of the amyloid precursor protein to secretases involved in the *β*-amyloidogenic pathway, and reduced LR11/SorLA expression is strongly correlated with AD neuropathology \[[@B27]\].

DHA also attenuates A*β* secretion in cytokine-stressed human neural cells, and this is accompanied by formation of neuroprotectin D1 \[[@B28]\]. 10,17S-docosatriene, also known as neuroprotectin D1, is a metabolite of DHA, which has been shown to have potent anti-inflammatory and neuroprotective effects in neural systems \[[@B29]\] and stroke \[[@B30]\]. DHA and neuroprotectin D1 were reduced in the hippocampus cornu ammonis region 1 (CA1) of AD brains, but not in the thalamus or occipital lobes of the same brains. Furthermore, expression of cytosolic phospholipase A~2~ and 15-lipoxygenase, which are key enzymes in neuroprotectin D1 biosynthesis, was altered in AD hippocampus. Neuroprotectin D1 also repressed the A*β* ~42~-triggered activation of proinflammatory genes and upregulated the antiapoptotic genes encoding Bcl-2, Bcl-xl, and Bfl-1(A1). The soluble amyloid precursor protein-alpha (APP-*α*) stimulated the biosynthesis of neuroprotectin D1 from DHA. These results suggest that the beneficial effects of DHA may in part also be mediated via the production of neuroprotectin D1, which induces anti-apoptotic and neuroprotective gene expression and consequently suppresses A*β* ~42~-induced neurotoxicity.

Positive effects of DHA treatment have not however been universally reported and a recent study by Arendash and co-workers found that a high omega-3 PUFA diet provided no significant benefit in terms of decreasing the levels of soluble/insoluble hippocampal A*β* levels or improving cognitive performance in neither amyloid precursor protein (APP)-sw and PS1 double transgenic or wild-type mice \[[@B31]\]. The authors did find that higher cortical levels of omega-6 PUFA in both the transgenic and wild type mice were associated with impaired cognitive function, as measured by the radial arm water maze and Morris water maze tests. It may be that if DHA is acting via a reduction in the steady-state levels of presenilin 1, as suggested by Green and co-workers \[[@B25]\], the overexpression of presenilin 1 in the transgenic mouse model used in this study overwhelms the capacity of DHA, and therefore this model may not accurately reflect the potential effects in patients, especially those affected by sporadic AD. Furthermore, the omega-3 PUFA experimental diet contained high levels of EPA, which may have antagonised the effects of DHA (4.7% EPA and 5.7% DHA expressed as % total fat) by for example competing for enzymes in the neuroprotectin D1 biosynthetic pathway.

An additional mechanism leading to a decrease in A*β* levels has been suggested by a study investigating the effect of omega-3 PUFA enrichment on gene expression in aged rats \[[@B32]\]. In this study, there was a 10-fold increase in transthyretin transcription following treatment, and since transthyretin is an A*β* protein scavenger \[[@B33]\], the authors concluded that the omega-3 PUFA-induced expression could potentially prevent amyloid aggregate formation. Indeed Serot and co-workers found an inverse relationship between transthyretin levels in cerebrospinal fluid and the severity of dementia in AD patients \[[@B34]\].

Several lines of evidence indicate that alterations in retinoid signalling lead to A*β* accumulation. For example, vitamin A deprivation results in deposition of A*β* in the cerebral blood vessels and downregulation of the retinoic acid receptor, RAR*α* in adult rat forebrain \[[@B35]\], and APP/presenilin 1 double mutant transgenic mice treated for 8 weeks with retinoic acid show significantly decreased A*β* deposition, tau phosphorylation, activation of microglia and astrocytes, attenuated neuronal degeneration and improved spatial memory compared to controls \[[@B36]\]. Retinoic acid regulates gene expression via its nuclear receptors: the retinoic acid receptors (RARs) and retinoid X receptors (RXRs) \[[@B37]\]. DHA and EPA have been reported to act as endogenous ligands of RXRs \[[@B38]--[@B40]\], and omega-3 PUFA supplementation has recently been shown to reverse age-related decreases in the levels of RAR*α*, RXR*α*, and RXR*β* in the aged rat forebrain \[[@B41]\]. It may be that omega-3 PUFAs are acting at a fundamental level of cell regulation by controlling gene expression via these receptors.

Omega-3 PUFA may also be acting at proliferator-activated receptors (PPARs), in particular PPAR*γ*. PPARs are involved in the control of the expression of a variety of genes involved in lipid energy metabolism and inflammation \[[@B42]\]. *In vitro* A*β* uptake and clearance from glial and neuronal medium is increased by PPAR*γ* \[[@B43]\]. In models of AD PPAR*γ* agonists reduce BACE1 transcription and expression in APP transgenic mice \[[@B44], [@B45]\], PPAR*γ* agonist and ibuprofen treatment reduce the expression of BACE1 and A*β* ~42~ amyloid deposits in the hippocampus and cortex of APPV717I mice \[[@B46]\], and PPAR*γ* agonists protect neurons against A*β*-induced mitochondrial damage, apoptosis, and oxidative stress \[[@B47]\]. Furthermore, treatment with PPAR*γ* agonists significantly improves measures of cognition in mild AD and mild cognitively impaired subjects compared to a placebo \[[@B48]\]. PPAR*γ*\'s are known to bind to and be activated by EPA, DHA, and DHA metabolites \[[@B49]--[@B51]\] and omega-3 PUFA supplementation has also been shown to reverse age-related decreases in the levels of PPAR*γ* in the aged rat forebrain \[[@B41]\].

There are a number of inflammatory events that occur in the brain as a response to the presence of A*β*. The key event appears to be the presence of activated microglia in the vicinity of the A*β*-containing plaques \[[@B52]\]. Microglial activation results in the sustained production of proinflammatory cytokines, growth factors, complement molecules, and adhesion molecules \[[@B53]\]. It has also been demonstrated that exposure of microglia to *β*-amyloid fibrils leads to the production of reactive oxygen species and neurotoxins \[[@B54]\] and activated microglia generate and release large numbers of superoxide ions \[[@B52]\], thereby increasing oxidative stress. The remainder of this paper will focus on this increased oxidative stress and inflammation and the potential role of omega-3 PUFA.

3. Oxidative Stress and Lipid Peroxidation {#sec3}
==========================================

The importance of increased oxidative stress, lipid peroxidation, and lipid peroxidation products has consistently been shown in the pathogenesis of AD \[[@B4]\]. For example, increased lipid peroxidation has been detected in the frontal, temporal, parietal, and occipital cortices of AD patients \[[@B55]\]. Moreover, significantly increased levels of the lipid peroxidation products 4-hydroxynonenal and acrolein, are found in the hippocampus/parahippocampal gyrus, superior and middle temporal gyrus, and cerebellum of subjects with mild cognitive impairment and early AD compared to age-matched controls \[[@B56]\], suggesting that lipid peroxidation occurs as an early event in the pathogenesis of AD. This is consistent with evidence from animal models of AD, where increased oxidative stress is also found in the APPsw (Tg2576) transgenic mouse model of AD amyloidosis. Cerebral cortical and hippocampal homogenates were found to have higher levels of lipid peroxidation than those from wild-type mice, and lipid peroxidation preceded amyloid plaque formation \[[@B57]\].

Isoprostanes are prostaglandin-like compounds formed *in situ* by nonenzymatic free radical-catalysed lipid peroxidation \[[@B58]\]. F~2~-isoprostanes are derived from the omega-6 PUFA, arachidonic acid, F~3~-isoprostanes from EPA and F~4~-isoprostanes, also called neuroprostanes, from DHA \[[@B59]--[@B61]\]. Measurement of isoprostanes provides a sensitive marker of *in vivo* lipid peroxidation \[[@B62]--[@B64]\]. Measurements comparing the level of isoprostanes and neuroprostanes between AD and matched controls in different regions of postmortem brains show a PUFA-specific pattern of lipid peroxidation. There is an increase in esterified neuroprostanes in the occipital and temporal lobes, whereas F~2~-isoprostanes in these regions are unchanged \[[@B65]\]. Similar results were found by Reich and coworkers, in the superior and middle temporal gyri, hippocampus, inferior parietal lobule, and cerebral cortex \[[@B66]\]. There were increased levels of neuroprostanes while F~2~-isoprostanes levels were unchanged. These results show a selective pattern of lipid peroxidation occuring in AD, whereby DHA appears especially vulnerable and arachidonic acid is unaffected.

These results may reflect more than simply the regional distribution of PUFA, since grey matter, where DHA is more abundant, has a significantly greater susceptibility to oxidative stress than white matter \[[@B64]\]. Levels of F~2~-isoprostanes and neuroprostanes was measured in the grey and white matter of brains from rats at intervals between 4 and 100 weeks of age. The level of neuroprostanes were consistently 20-fold greater than F~2~-isoprostanes, whereas DHA content was only two-fold greater than arachidonic acid, suggesting that DHA is especially prone to oxidative stress.

PUFAs are particularly susceptible to lipid peroxidation and as such are a potential abundant source of destructive peroxidation products. The *in vitro* peroxidisability of unsaturated fatty acids is linearly dependent upon the number of bis-allylic positions, such that the peroxidisability of DHA is five times greater than that of the omega-6 PUFA linoleic acid, which contains only two double bonds \[[@B67]\]. This increased susceptibility would help to explain the vulnerability of membrane DHA to lipid peroxidation and may also suggest that elevating omega-3 PUFA intake *in situ*ations of increased oxidative stress, such as AD, would further increase production of toxic peroxidation products.

Although some studies have shown increased lipid peroxidation following dietary supplementation with DHA and EPA in plasma, liver, and kidney \[[@B68]--[@B73]\] others have shown that EPA and DHA enriched diets do not increase levels of lipid peroxidation \[[@B74], [@B75]\]. Indeed, rather than increasing lipid peroxidation DHA has been shown to be neuroprotective by actually decreasing lipid peroxidation in the brain \[[@B76]--[@B78]\]. For example, rats being fed a diet enriched with DHA showed a significantly reduced level of cerebral lipid peroxide compared to controls \[[@B78]\], and the level of peroxidation was inversely related to the cerebral DHA/arachidonic acid ratio \[[@B77]\]. Furthermore, Tg2576 transgenic mice being fed a DHA deficient diet have significantly elevated levels of oxidised proteins compared to the control group, whereas the levels of oxidised proteins were significantly reduced in a DHA supplemented group \[[@B79]\].

Overall, these results suggest that DHA may function in an antioxidant role, at least in the brain. Yavin and colleagues have suggested a number of potential mechanisms for these observed antioxidant effects \[[@B80]\]. Membrane bound DHA may act as a trap for reactive oxygen species, DHA may be able to enhance the activity of endogenous antioxidant enzymes, or phosphatidylethanolamine plasmalogens containing DHA may contain intrinsic antioxidant properties. DHA has also been shown to induce antioxidant defences by enhancing cerebral activities of catalase, glutathione peroxidase, and levels of glutathione \[[@B81]\]. Furthermore, work by Green and colleagues suggests that DHA may reduce reactive oxygen species production by increasing nitric oxide production, which may decrease the cellular oxygen pool and consequently reduce the amount of reactive oxygen species and generate lipid peroxides \[[@B82]\].

4. Fatty Acid Composition {#sec4}
=========================

The increased lipid peroxidation and concomitant damage to membrane PUFA have the potential to significantly reduce the brain levels of PUFA and specifically DHA. However, a recent review found that low DHA is not consistently observed in plasma or brain of AD patients \[[@B83]\]. Although the authors did note wide variability between studies and suggested that it may be too early to draw any reliable conclusions. They did however report AD to be consistently associated with significantly lower phosphatidylethanolamine and phosphatidylcholine concentrations in the frontal cortex and hippocampus and the DHA content of hippocampal phosphatidylethanolamine is significantly lower compared to age-matched controls.

DHA is particularly enriched in phosphatidylethanolamine \[[@B84]\], and this is therefore an important cellular store of DHA. Furthermore, in the hippocampal CA1 region of AD patients unesterified DHA and neuroprotectin D1 levels are reported to be about one-half and one-twentieth of those in age-matched controls, respectively \[[@B28]\]. It may therefore be hypothesised that although DHA decreases do not appear widespread or large in magnitude, these selective decreases in the hippocampus may have profound effects on specific cellular pools and the subsequent production of key DHA metabolites.

5. Inflammation {#sec5}
===============

In comparison with nondemented elderly subjects virtually all the inflammatory cytokines and chemokines so far investigated appear to be upregulated in AD patients, including IL-1*β*, IL-6, TNF-*α*, IL-8, transforming growth factor-*β* (TGF-*β*), and macrophage inflammatory protein-1*α* (MIP-1*α*), for reviews see \[[@B3], [@B85]\]. The most notable proinflammatory cytokines produced by microglial cells, IL-1*α* and IL-1*β* are found throughout the brain of AD patients at autopsy \[[@B86]\]. IL-1*β* induces formation of reactive oxygen species, causing lipid peroxidation, and depletes membrane PUFA levels \[[@B87], [@B88]\]. IL-1*β* also triggers microglial activation and increases expression of amyloid precursor protein \[[@B89], [@B90]\]. Age-related increases in IL-1*β* are coupled with increased activity of MAPK, c-jun-N-terminal kinases (JNK, a stress activated MAP kinase), and p38 kinase and enhanced caspase-3 activity (an effector of apoptosis) \[[@B91]\]. MAP kinases mediate many specific cellular responses, including apoptosis and stress responses.

EPA supplementation has been reported to decrease the production of proinflammatory cytokines in rodents. For example, EPA reversed the age-related increases in IL-1*β* concentration and activation of p38 and caspase-3 \[[@B92]\]. The EPA supplementation also restored age-related decreases in arachidonic acid and DHA concentrations and decreased reactive oxygen species accumulation. It has also recently been shown that IL-1*β* reduces acetylcholine release in rats, which correlates with memory deficits, and EPA supplementation prevents the effects of IL-1*β* and significantly improves memory \[[@B93]\]. Degeneration of cholinergic neurons is thought to contribute to cognitive impairments in AD \[[@B94]\].

EPA and DHA are the precursors of a diverse array of second messengers, called resolvins and docosanoids, with potent anti-inflammatory and proresolving actions \[[@B30], [@B95], [@B96]\]. Resolution of inflammation has traditionally been thought of as a passive process; however, recent evidence suggests that resolution is an active process involving the biosynthesis of local lipid derived mediators within the resolution phase, called resolvins \[[@B96]\]. The D class resolvins, derived from DHA block TNF-*α*-induced IL-1*β* transcripts in brain \[[@B95]\] and resolvin E1 (RvE1), produced from EPA, reduces IL-12 production via the ChemR23 receptor \[[@B97]\]. 10,17S-docosatriene, also known as neuroprotectin D1 is produced from DHA \[[@B30]\] and potently blocks the generation of both TNF-*α* and IFN-c by stimulated T cells \[[@B98]\]. Together, these data suggest that the omega-3 PUFA metabolites have the potential to decrease inflammation by decreasing inflammatory cytokine production.

Most human dietary supplementation studies investigating the effects of omega-3 PUFA on cytokine production have typically examined the effects of high EPA rather than DHA preparations \[[@B99]--[@B105]\]. EPA and DHA have differing effects on inflammatory response and they should not be considered as having mechanistic equivalence \[[@B106], [@B107]\]. Furthermore, EPA and DHA produce distinct metabolites, and it may be that DHA is the more potent immunological modulator via production of neuroprotectin D1. A recent trial supplemented 174 AD patients with a high DHA preparation (1.7 g DHA and 0.6 g EPA or placebo for 6 months) \[[@B108]\]. The DHA/EPA supplemented patients had significantly reduced IL-1*β*, and IL-6 release from lipopolysaccharide stimulated peripheral blood mononuclear cells compared to the placebo group, although TNF-*α*, IL-8, IL-10 and granulocyte colony-stimulating factor were not affected.

The mechanism by which DHA and EPA are able to attenuate inflammatory processes has yet to be elucidated; however it is likely that these observed effects are mediated at the level of gene regulation by modifying the actions of transcription factors, with nuclear factor-kappa B (NF-*κ*B) a being potential candidate. NF-*κ*B has many diverse functions in the nervous system and regulates a large number of genes encoding many inflammatory cytokines, such as IL-1*β*, IL-6, INF-*α*, and MCP-1; however, it also regulates anti- and proapoptotic proteins including Bcl-2, Bcl-xl, Bcl-xs, Bax, cyclooygenase-2, and inducible nitric oxide synthase \[[@B109]\]. NF-*κ*B activation occurs following a signalling cascade initiated by external inflammatory stimuli and involves the phosphorylation and subsequent degradation of the I*κ*B inhibitory subunit, which allows NF-*κ*B translocation to the nucleus and the subsequent activation of expression of target genes \[[@B109]\].

The role of NF-*κ*B appears to be determined by cell type and timing of activation. For example, activation of NF-*κ*B in neurons associated with amyloid deposits is currently thought to be neuroprotective, whereas induction of NF-*κ*B in glia may be neurotoxic. For reviews see \[[@B109]--[@B111]\]. EPA or omega-3 PUFA supplemented media decreases lipopolysaccharide-induced activation of NF-*κ*B and TNF-*α* levels in cultured macrophages \[[@B112], [@B113]\] and monocytes \[[@B114]\], importantly, DHA suppresses IL-6 production and activation of NF-*κ*B in lipopolysaccharide/interferon-*γ* stimulated glial cells \[[@B115]\], suggesting omega-3 PUFAs may have direct effects on inflammatory cytokine production via effects on the NF-*κ*B signalling pathway. However, their site of action in this pathway and specific effects in neurons are yet to be determined.

6. Conclusions {#sec6}
==============

Although there are strong correlations between low tissue levels of omega-3 PUFA and increased risk of AD, and low dietary intakes of omega-3 PUFA and cognitive decline and AD \[[@B116], [@B117]\], the results of dietary intervention studies have so far failed to live up to expectations raised by the preclinical and epidemiological studies. In the first study to look at the effects of omega-3 PUFA in AD, Yehuda and colleagues conducted a 4 week double-blind trial with 100 AD patients \[[@B118]\]. The supplemented group showed improvements in mood, cooperativity, short-term memory, appetite, sleep, and spatial orientation, whereas no improvements were seen in the placebo group. A subsequent pilot study investigated the effects of 500 mg EPA given twice daily for 12 weeks in patients with AD \[[@B119]\]. No differences were found and the authors concluded that EPA had no effects on cognition. A larger study in 174 patients found that administration of 1.7 g of DHA and 0.6 g of EPA per day for 6 months in patients with mild to moderate AD did not delay the rate of cognitive decline \[[@B120]\], although, positive effects were observed in a small subgroup of patients with very mild AD (MMSE \>27 points).

Therefore, current evidence appears to indicate that the beneficial effects of omega-3 PUFAs are more related to limiting the progression of cognitive decline, as most clinical trials have so far failed to demonstrate the efficacy of omega-3 PUFA treatment after the onset of AD symptoms. However, it should be noted that preclinical studies have focused on the effects of DHA and its metabolites, whereas clinical studies have investigated EPA, or may have used insufficient doses of DHA. In brain tissue, DHA-derived metabolites promote resolution and protect neural cells from neurodegeneration \[[@B121]\] and may therefore be the more important omega-3 PUFA in modulating the secretion of cytokines and inhibiting neuroinflammation and oxidative stress in AD. Furthermore, recent evidence suggests that the beneficial effects of omega-3 PUFA on reducing the risk of dementia and AD may be reduced by the presence of the apolipoprotein E *ε*4 (*APOE* *ε*4) allele \[[@B122]--[@B124]\]. It is hoped that future clinical studies will help clarify these issues and the relative roles and utility of DHA and EPA in the treatment of AD.
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